Sunday November 15 2026 News
Sections
About
Robin Hayes
Pancreatic cancer is one of the deadliest forms of cancer, and it’s on track to become even more lethal. By 2030, it is projected to be the second-leading cause of cancer deaths globally. Often diagnosed at a late stage, the disease is notoriously difficult to treat, with survival rates remaining dismally low despite decades of research.
· 4 min read
Sloane Powers
Patients with active cancer who experienced blood clots, known medically as venous thromboembolism (VTE), showed favorable outcomes with a lower dose of apixaban. This was demonstrated by the recent API-CAT trial, which found that a reduced dose effectively prevented recurrence of VTE while substantially lowering the risk of bleeding, compared to the standard higher dose.
· 3 min read
Ash Cooper
A groundbreaking study from Baylor College of Medicine has uncovered a novel mechanism by which triple negative breast cancer (TNBC) evades treatment—through the accumulation of specific fatty acids that suppress the immune response and drive therapy resistance.
· 4 min read
Robin Hayes
In a groundbreaking phase 1 clinical trial at City of Hope®, one of the largest and most advanced cancer research and treatment centers in the U.S., researchers are exploring an innovative approach to treating rectal cancer. The trial seeks to transform rectal cancer—a disease notorious for its resistance to radiation—into a form that is much more responsive to radiation and chemotherapy. This new strategy, which uses the investigational drug papaverine, could pave the way for less invasive treatment options and dramatically improve the quality of life for patients.
· 6 min read
Robin Hayes
This blog post discusses the groundbreaking collaboration between Aston University and the Royal Orthopaedic Hospital in developing an innovative injectable paste for bone cancer treatment. The research focuses on using gallium-doped bioglass to enhance therapeutic efficacy while minimizing side effects. By delivering targeted therapy directly to tumor sites, this advancement aims to improve patient outcomes, reduce recurrence rates, and expedite recovery times. This interdisciplinary effort symbolizes a significant leap in oncology care, offering hope for better treatment solutions and improved quality of life for bone cancer patients.
· 5 min read
Sage Bennett
Explore the groundbreaking Radioligand Program developed by Dana-Farber Cancer Institute and Gustave Roussy, aimed at revolutionizing cancer treatment. This initiative focuses on the application of radioligands for targeted therapy, improving patient outcomes with reduced side effects. Join experts like Professors Toni Choueiri and Karim Fizazi at the 'Radiopharmaceutical Therapy Meets Oncology' conference to learn about advancements in precision oncology, clinical applications, and the role of collaborative initiatives in cancer care. Stay informed on the latest research and treatments transforming the oncology landscape.
· 5 min read
Robin Hayes
Explore the groundbreaking research on the cdkn2a gene and its dual role in esophageal cancer. Learn how this gene, previously viewed solely as a tumor suppressor, may also provide protective mechanisms in early cancer development. This blog post delves into recent findings, implications for cancer prognostics, and future directions in cancer therapy and prevention strategies.
· 5 min read
Adjust how this site looks and behaves for you. Your choices are saved on this device only.
Darker text and stronger lines, borders and links.
Shows text in the OpenDyslexic typeface.
More space between lines, letters and words.
Makes every link easy to spot.
A bold outline shows where you are when using a keyboard.
Turns off animations, transitions and autoplaying video.
